請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32329
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳為堅(Wei J. Chen) | |
dc.contributor.author | Chian-Jue Kuo | en |
dc.contributor.author | 郭千哲 | zh_TW |
dc.date.accessioned | 2021-06-13T03:43:06Z | - |
dc.date.available | 2013-10-03 | |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-28 | |
dc.identifier.citation | 1. Cho AK (1990) Ice: a new dosage form of an old drug. Science 249: 631-634.
2. MacKenzie RG, Heischober B (1997) Methamphetamine. Pediatrics in Review 18: 305-309. 3. United Nations Office on Drugs and Crime (2008) 2008 World Drug Report. Geneva: United Nations. 4. Farrell M, Marsden J, Ali R, Ling W (2002) Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction 97: 771-772. 5. Parry CD, Myers B, Pluddemann A (2004) Drug policy for methamphetamine use urgently needed. S Afr Med J 94: 964-965. 6. Maxwell JC, Rutkowski BA (2008) The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 27: 229-235. 7. Darke S, Kaye S, McKetin R, Duflou J (2008) Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27: 253-262. 8. Kaye S, McKetin R, Duflou J, Darke S (2007) Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 102: 1204-1211. 9. Logan BK, Fligner CL, Haddix T (1998) Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43: 28-34. 10. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, et al. (2004) Psychiatric symptoms in methamphetamine users. Am J Addict 13: 181-190. 11. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, et al. (2008) Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict 17: 24-27. 12. Singleton J, Degenhardt L, Hall W, Zabransky T (2009) Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend 105: 1-8. 13. Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CD (2004) Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction 99: 53-60. 14. Lejckova P, Mravcik V (2007) Mortality of hospitalized drug users in the Czech Republic. Journal of Drug Issues 37: 103-118. 15. Fugelstad A, Annell A, Rajs J, Agren G (1997) Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981-1992. Acta Psychiatr Scand 96: 169-175. 16. Degenhardt L, Roxburgh A, Barker B (2005) Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. J Clin Forensic Med 12: 187-195. 17. Zhu BL, Oritani S, Shimotouge K, Ishida K, Quan L, et al. (2000) Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas. Forensic Sci Int 113: 443-447. 18. Karch SB, Stephens BG, Ho CH (1999) Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 44: 359-368. 19. Kaye S, Darke S, Duflou J, McKetin R (2008) Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 103: 1353-1360. 20. Chen CC, Kuo CJ, Tsai SY (2001) Causes of death of patients with substance dependence: a record-linkage study in a psychiatric hospital in Taiwan. Addiction 96: 729-736. 21. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association. 22. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association. 23. Lin SK, Ball D, Hsiao CC, Chiang YL, Ree SC, et al. (2004) Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci 58: 206-212. 24. Kuo CJ, Tsai SY, Liao YT, Conwell Y, Lin SK, et al. (2010) Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case-control study. J Clin Psychiatry doi:10.4088/JCP.09m05360gry. 25. Kuo CJ, Tsai SY, Lo CH, Wang YP, Chen CC (2005) Risk factors for completed suicide in schizophrenia. J Clin Psychiatry 66: 579-585. 26. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492-499. 27. Breslow NE, Day, N.E. (1987) Statistical methods in cancer research. Volume II. The design and analysis of cohort studies. Lyon: International agency for research on cancer. 28. Cytel Software Corp. (1999) Egret for windows [computer program]. Version 2.0.31. Cambridge, Mass. 29. Albertson TE, Derlet RW, Van Hoozen BE (1999) Methamphetamine and the expanding complications of amphetamines. West J Med 170: 214-219. 30. Mendelson J, Jones RT, Upton R, Jacob P, 3rd (1995) Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 57: 559-568. 31. Darke S, Degenhardt, L., Mattick, R. (2007) Mortality amongst illicit drug users. Epidemiology, causes and intervention. Cambridge: Cambridge University Press. 32. Joung IM, Stronks K, van de Mheen H, Mackenbach JP (1995) Health behaviours explain part of the differences in self reported health associated with partner/marital status in The Netherlands. J Epidemiol Community Health 49: 482-488. 33. Wyke S, Ford G (1992) Competing explanations for associations between marital status and health. Soc Sci Med 34: 523-532. 34. Eng PM, Rimm EB, Fitzmaurice G, Kawachi I (2002) Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease incidence in men. Am J Epidemiol 155: 700-709. 35. McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction 101: 1473-1478. 36. Hall W, Hando J, Darke S, Ross J (1996) Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 91: 81-87. 37. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, et al. (2008) Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat 35: 445-450. 38. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, et al. (2003) Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med 33: 1407-1414. 39. Davila EP, Christ SL, Caban-Martinez AJ, Lee DJ, Arheart KL, et al. (2010) Young adults, mortality, and employment. J Occup Environ Med 52: 501-504. 40. Lundin A, Lundberg I, Hallsten L, Ottosson J, Hemmingsson T (2010) Unemployment and mortality--a longitudinal prospective study on selection and causation in 49321 Swedish middle-aged men. J Epidemiol Community Health 64: 22-28. 41. Mahoney JJ, 3rd, Kalechstein AD, De La Garza R, 2nd, Newton TF (2008) Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am J Addict 17: 83-98. 42. Bell DS (1965) Comparison of Amphetamine Psychosis and Schizophrenia. Br J Psychiatry 111: 701-707. 43. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, et al. (1993) The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch Gen Psychiatry 50: 527-540. 44. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ (2005) Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187: 9-20. 45. Blakely TA, Collings SC, Atkinson J (2003) Unemployment and suicide. Evidence for a causal association? J Epidemiol Community Health 57: 594-600. 46. Qin P, Agerbo E, Mortensen PB (2003) Suicide risk in relation to socioeconomic, demographic, psychiatric, and familial factors: a national register-based study of all suicides in Denmark, 1981-1997. Am J Psychiatry 160: 765-772. 47. Hawton K (1987) Assessment of suicide risk. Br J Psychiatry 150: 145-153. 48. Yen CF, Shieh BL (2005) Suicidal ideation and correlates in Taiwanese adolescent methamphetamine users. J Nerv Ment Dis 193: 444-449. 49. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, et al. (2000) Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 12: 480-484. 50. Rothman KJ, Greenland, S., Lash, T.L. (2008) Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins. 51. Hollingshead A, Rhdlich, F. (1958) Social class and mental illness. New York, NY: Wiley. 52. Brebion G, Ohlsen RI, Pilowsky LS, David AS (2008) Visual hallucinations in schizophrenia: confusion between imagination and perception. Neuropsychology 22: 383-389. 53. WHO (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guildlines. Geneva, Switzerland: World Health Organization. 54. Vocci FJ, Appel NM (2007) Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 102 Suppl 1: 96-106. 55. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63: 332-339. 56. Agerbo E (2005) Effect of psychiatric illness and labour market status on suicide: a healthy worker effect? J Epidemiol Community Health 59: 598-602. 57. Agerbo E (2007) High income, employment, postgraduate education, and marriage: a suicidal cocktail among psychiatric patients. Arch Gen Psychiatry 64: 1377-1384. 58. Cheng AT (1995) Mental illness and suicide. A case-control study in east Taiwan. Arch Gen Psychiatry 52: 594-603. 59. Busch KA, Fawcett J, Jacobs DG (2003) Clinical correlates of inpatient suicide. J Clin Psychiatry 64: 14-19. 60. United Nations Office on Drugs and Crime (2008 (http://www.unodc.org/documents/scientific/ATS/Global-ATS-Assessment-2008-Web.pdf)) Amphetamines and Ecstasy: 2008 Global ATS Assessment. Vienna: United Nations Office on Drugs and Crime. 61. Chen CY, Wu PN, Su LW, Chou YJ, Lin KM (2010) Three-year mortality and predictors after release: a longitudinal study of the first-time drug offenders in Taiwan. Addiction 105: 920-927. 62. Lai SW, Chang WL, Peng CY, Liao KF (2007) Viral hepatitis among male amphetamine-inhaling abusers. Intern Med J 37: 472-477. 63. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, et al. (2008) Harrison's Principles of Internal Medicine. New York: McGraw-Hill Professional. 64. Abdel Raheem K, Ismael N, Saad A, el-Sayad S (1997) Gluconeogenic activity in response to chronic administration of amphetamine sulphate and drug withdrawal. Gen Pharmacol 29: 687-690. 65. Zalis EG, Lundberg GD, Knutson RA (1967) The pathophysiology of acute amphetamine poisoning with pathologic correlation. J Pharmacol Exp Ther 158: 115-127. 66. Catravas JD, Waters IW, Hickenbottom JP, Davis WM (1977) The effects of haloperidol, chlorpromazine and propranolol on acute amphetamine poisoning in the conscious dog. J Pharmacol Exp Ther 202: 230-243. 67. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, et al. (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188: 122-127. 68. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173: 325-329. 69. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, et al. (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71: 103-108. 70. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International Consensus Study of Antipsychotic Dosing. Am J Psychiatry 167: 686-693. 71. Kuo CJ, Liao YT, Chen WJ, Tsai SY, Lin SK, et al. (2011) Causes of death of patients with methamphetamine dependence: A record-linkage study. Drug Alcohol Rev. 72. Sheridan RD, Turner SR, Cooper GJ, Tattersall JE (2005) Effects of seven drugs of abuse on action potential repolarisation in sheep cardiac Purkinje fibres. Eur J Pharmacol 511: 99-107. 73. Haning W, Goebert D (2007) Electrocardiographic abnormalities in methamphetamine abusers. Addiction 102 Suppl 1: 70-75. 74. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S (1960) The electrocardiogram in population studies. A classification system. Circulation 21: 1160-1175. 75. Prineas RJ, Crow RS, Zhang Z-M (2010) The Minnesota code manual of electrocardiographic findings. London: Springer-Verlag. 76. Prineas RJ, Crow RS, Blackburn H (1982) The Minnesota Code Manual of Electrocardiographic Findings. . In: John Wright PSB Inc., editor. Boston: MA. 77. Kuo CJ, Tsai SY, Liao YT, Conwell Y, Lin SK, et al. (2011) Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case-control study. J Clin Psychiatry 72: 487-493. 78. Wu HM, Tien YJ, Chen C (2010) Gap: A graphical environmental for matrix visualization and cluster analysis. Comput Stat Data Anal 54: 767-778. 79. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, et al. (1998) Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 155: 1214-1220. 80. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847. 81. Cohen J (1987) Statistical power analysis for the behavioral sciences; Cohen J, editor. Hillsdale, New Jersey: Lawrence Erlbaum Associates. 82. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, et al. (2009) AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 53: 982-991. 83. Cubeddu LX (2003) QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 10: 452-457. 84. Gomes-da-Silva J, de Miguel R, Fernandez-Ruiz J, Summavielle T, Tavares MA (2004) Effects of neonatal exposure to methamphetamine: catecholamine levels in brain areas of the developing rat. Ann N Y Acad Sci 1025: 602-611. 85. Clements-Jewery H, Kanaganayagam GS, Kabra R, Curtis MJ (2006) Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. Br J Pharmacol 147: 468-475. 86. Chakko S, Sepulveda S, Kessler KM, Sotomayor MC, Mash DC, et al. (1994) Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol 74: 710-713. 87. Levin KH, Copersino ML, Epstein D, Boyd SJ, Gorelick DA (2008) Longitudinal ECG changes in cocaine users during extended abstinence. Drug Alcohol Depend 95: 160-163. 88. Derlet RW, Rice P, Horowitz BZ, Lord RV (1989) Amphetamine toxicity: experience with 127 cases. J Emerg Med 7: 157-161. 89. Lan KC, Lin YF, Yu FC, Lin CS, Chu P (1998) Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 97: 528-533. 90. Fukunaga T, Mizoi Y, Adachi J (1987) Methamphetamine-induced changes of peripheral catecholamines: an animal experiment to elucidate the cause of sudden death after methamphetamine abuse. Nihon Hoigaku Zasshi 41: 335-341. 91. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, et al. (1991) Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 14: 352-358. 92. Yu Q, Larson DF, Watson RR (2003) Heart disease, methamphetamine and AIDS. Life Sci 73: 129-140. 93. McGuigan MA (1984) Toxicology of drug abuse. Emerg Med Clin North Am 2: 87-101. 94. Chan P, Chen JH, Lee MH, Deng JF (1994) Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J Toxicol Clin Toxicol 32: 147-155. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32329 | - |
dc.description.abstract | 研究緣起:
自從1990年代初期, 甲基安非他命的濫用問題已成為全球之非法藥物成長最快速之一, 特別是在東南亞、澳洲, 及北美地區。甲基安非他命被報告會造成身體和精神之傷害; 前者包括心臟血管疾病, 後者則包括憂鬱、精神病症狀及自殺。甲基安非他命亦導致早期死亡的危險增加。然而, 關於死亡預後或死亡原因的實證資料在文獻中相當少。此外, 甲基安非他命已知對人體具有心臟毒性。心電圖為非侵犯性、低成本及廣泛使用之檢測工具, 本研究假設其可能成為評估甲基安非他命者各項傷害及預後的工具。 最近有回顧性文章顯示曾有8個使用世代族群探討安非他命死亡預後, 但只有其中的3個使用超過500個研究樣本。本研究計劃選擇一大型甲基安非者世代族群 (N=1254), 其均曾因甲基安非他命相關問題住院治療; 與死亡檔連結將可追蹤其死亡狀態。由巢式個案對照研究和標準化病歷回顧, 計劃分別探討自殺死亡和自殺死亡的危險因子。此外, 為探討此特殊族群的心電圖異常, 本研究將選擇一外部健康族群成為控制組, 以便與甲基安非他命組作比較。 目的: 目的一: 探討甲基安非他命者的長期死亡率及死因; 目的二: 探討甲基安非他命者自殺死亡的危險和保護因子; 目的三: 探討甲基安非他命者自然死亡的危險因子; 目的四: 探討甲基安非他命者的心電圖異常。 研究設計與方法: 第一部份: 本研究將收集於1990/1/1至2007/12/31, 在北部某一精神科專科醫院住院的所有甲基安非他命依賴(依DSM-III-R和DMS-IV診斷標準)的病患, 定義為世代族群和進行回溯性研究。由一初步簡要的病歷回顧收集每位個案的診斷和社會人口變項資料。經連結同時期的全國死亡檔, 以獲得死亡資料並計算標準死亡比(SMR); 估計總共約為150位死亡個案。 第二部份: 基於第一部份的資料連結, 有38位因自殺死亡, 定義為個案組; 利用密度抽樣(density sampling), 由原來世代族群中以1:2比例選取適當的控制組, 配對條件為性別、年齡不相差5歲及相同的指標住院年。之後使用詳細標準病歷回顧方式, 收集社會人口學、精神病理學及臨床相關變項。使用多變項邏輯式迴歸, 分析與自殺死亡相關的因子。 第三部份. 基於第一部份的資料連結, 有45位為因自然死亡, 定義為個案組; 利用密度抽樣(density sampling), 由原來世代族群中以1:4比例選取適當的控制組, 配對條件為性別、年齡不相差5歲及相同的指標住院年。由詳細標準病歷回顧方式, 收集相關臨床變項及實驗室指標。使用多變項邏輯式迴歸, 分析與自然死亡相關的因子。 第四部份. 根據甲基安非他命者的性別和年齡分層, 選擇一個曾經參與身體健檢之健康族群 (N=300)成為對照組, 以探討心電圖的異常。為對心電圖標準判讀, 本研究將二組的心電圖送往Epidemiological Cardiology Research Center (EPICARE), Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; 且採用Minnesota分類作標準判讀。判讀時該機構不清楚研究樣本之分組(甲基安非他命組或正常組)。 第四部份. 本研究收集二個樣本, 分別選擇由上述世代族所選擇的一個甲基安非他命(N=387), 以及一個健康族群(n=300); 之後依Minnesota分類標準以進行詳細心電圖的比較。利用一標準病歷回顧方式, 收集每位個案的社會人口學和臨床資訊。標準判讀心電圖的實驗室(Epicare)對所有的臨床和分組資料均不知。心電圖根據下列五個主要的分類區分為正常和不正常(輕度和重度): 心肌梗塞或缺氧, 傳導缺損, 心律不整, 心房或心室肥大, 以及心室再極化延長。甲基安非他命與健康組間的心電圖標準化差異, 為根據此二組之特質差異進行調整。根據巢式個案對照研究設計, 本研究亦分別探討心電圖異常與所有死因、自然死因、非自然死因和心臟血管疾病死亡的相關性。 結果: Part I. 在研究過程中, 有130位個案死亡; 其中有63.1%為非自然死亡, 而36.9%為自然死亡。相對於一般族群, 本研究世代族群有過多死亡(SMR=6.02), 而女性比男性在非自然死亡部份, 有較高的SMR (p=0.001)。 Part II. 有關在研究期間的最後一次住院(latest admission), 財務獨立(financial independence)降低自殺危險性(adjusted risk ratio [aRR] = 0.33, p<.05), 而視幻覺(visual hallucinations)增高自殺危險性(aRR=2.57, p<.05)。對於出院後的期間(post-discharge period), 財務獨立仍降低自殺危險性(aRR] = 0.11, p<.05), 而自殺企圖(aRR = 8.78, p < .05)及憂鬱症候群(aRR = 3.28, p = .059)則增加自殺危險性。 Part III. 對於指標住院(index admission)的臨床特質, 以自然死亡為預後的多變項邏輯式迴歸顯示: 相對於AST正常組(<40 U/L), AST明顯上升組(>80U/L)的調整後危險比為其10.69 (p < .001), 而輕度上升組(40-80 U/L)之危險比則為4.71 (p < .01)。若以ALT而言, 明顯上升組與輕度上升組的5.22 (p < .01) and 5.13 (p < .01)倍。若以研究期間的最後一次住院, 使用抗精神病藥物則與低危險性有相關性。 Part IV. 在調整甲基安非他命組與正常組之間的差異, 連續心電圖指標中, 只有三個指標的調整z分數大於0.5 (medium effect size), 包括PR duration (-0.9422), QTc duration (0.9062) and QTI (0.9021)。這些指標的差異性均約在一個標準差。 甲基安非他命組比控制組有較高的心律不整比例(17.6% vs. 8.7%, p=0.001), 而其他四個指標則在二組無明顯差異。甲基安非他命組比控制組較易有心電圖重度異常(4.4% vs. 1.3%, p=0.015), 也容易有輕度異常(47.8% vs. 39.7%, p=0.003)。 此外, 在甲基安非他組中, 若依甲基安非他命使用的狀態, 與最近使用者(recent users)比較, 現在使用者(current users)除有較快的心跳外, 在其他指標並無明顯異常。心電圖的異常與甲基安非他命使用長短(duration of use)無明顯差異。 結論: Part I. 在死亡者中, 有不少為自然死亡, 但大多為死於非自然死亡。此發現提供明顯的證據對此特殊族群有價值的洞察。 Part II. 在此族群中所發現的自殺死亡保護和危險因子, 將可作為臨床介入和預防的重要參考。 Part III. 此研究強調甲基安非他命造成多器官系統損壞, 可能與自然死亡相關; 對特定具有升高AST/ALT的個案需要密切追蹤。 Part IV. 此研究確認在甲基安非依賴者的心電圖異常, 尤其是PR interval縮短和QT interval延長。此外, 建議能篩檢具有心電圖異常者, 此可能為潛在可治療心臟毒性的個案。 | zh_TW |
dc.description.abstract | Background:
Since the 1990s, the abuse of methamphetamine has become one of the fastest growing illicit drug problems worldwide, particular in South-east Asia, Australia, and North America. Methamphetamine (MAMP) was reported to induce the physical and mental harms; the earlier ones include cardiovascular disorders and the later include depression, psychosis, and suicide. Methamphetamine use leads to increased likelihood of premature death. However, the empirical information regarding the mortality outcome and causes of death is limited in the literature. Besides, methamphetamine has a well-known cardiotoxicity in the humankind. Given the non-invasiveness, low cost, and wide availability, the electrocardiogram (ECG) may be a useful tool for assisting in the clinical assessment of various harms and prediction of future outcome in patients with methamphetamine dependence. A recent systematic review highlighted only eight cohort studies that investigated the mortality of amphetamine users in the literature, and three of these studies had a sample size of 500 or larger. The project was proposed to follow up a large cohort of inpatients (N=1254) with methamphetamine dependence who had ever been hospitalized due to methamphetamine-related problems by means of a record-linkage study for obtaining their mortality information. Based on the nested case-control study design and standardized chart reviewing process, the risk factors for suicide mortality and natural death separately are explored. Additionally, a healthy study group will be enrolled as the control group for the comparison of electrocardiographic abnormalities with the methamphetamine-dependent group. Design and Methods: Part I. In a consecutive series of 1,254 inpatients with methamphetamine dependence (diagnosed according to DSM-III-R and DSM-IV criteria) admitted to a psychiatric center in northern Taiwan from January 1, 1990, through December 31, 2007, was defined as the cohort and retrospectively studied. Diagnostic and sociodemographic data for each subject were extracted from the medical records based on a brief chart review process. Mortality data were obtained by linking to the National Death Certification System (1990-2007) and standardised mortality ratios (SMRs) were estimated. Totally, around 150 deceased subjects are estimated to be found. Part II. Based on the link process in part I, 38 deaths due to suicide were identified as cases, and 76 controls were randomly selected using risk-set density sampling in a 2:1 ratio, matched for age, sex, and the year of index admission. A standardized comprehensive chart review process was adopted to collate sociodemographic, psychopathological and clinical information for each study subject. Multivariate conditional logistic regression analysis was used to identify correlates of suicide among these patients. Part III. Based on the link process in part I, forty-five cases died of natural causes, each of which was then matched with four living controls on age, sex and the year of index admission using risk-set sampling. Clinical data and laboratory results during hospitalization were obtained through a standardized review of medical records. Part IV. This study enrolled two groups, a large-size roster of subjects (N=387) derived from a cohort of inpatients with methamphetamine dependence and a healthy control group (n=300), for the comparison of comprehensive ECG indices based on the Minnesota code classification. A standardized chart review process was adopted to collate sociodemographic and clinical information for each study subject. The laboratory (Epicare) for standardized ECG readings was blinded to all of clinical data and grouping information. ECG readings were classified into normal and abnormal (minor, major) by 5 categorical indices: myocardial infarction or ischemia, conduction defect, arrhythmias, atrial enlargement or ventricular hypertrophy, and prolonged ventricular repolarization. Differences of indices of electrocardiograms between the two groups were standardized against those of a healthy control group, with adjustment for covariates derived from the differences between methamphetamine and control groups. Based on the nested case-control study, this study also explored the ECG abnormality in association with all-cause, natural, unnatural and cardiovascular deaths separately. Results: Part I. During the study period, 130 patients died. Of them, 63.1% died from unnatural deaths, while the remaining 36.9% died from natural deaths. Relative to the general population, the cohort had excessive mortality (SMR of 6.02) and women had a higher SMR for unnatural deaths than men (p = 0.001). Part II. For the sociodemographic and symptom profiles at the latest admission, financial independence lowered the risk (adjusted risk ratio aRR = 0.33, p < .05) whereas visual hallucinations elevated the risk (aRR = 2.57, p < .05) for suicide. For the profiles during the post-discharge period, financial independence (aRR = 0.11, p < .05) remained associated with reduced risk to suicide, whereas suicide attempt (aRR = 8.78, p < .05) and depressive syndrome (aRR = 3.28, p = .059) were associated with increased risk of suicide. Part III. For clinical characteristics at the index admission, multivariate conditional logistic regression revealed that the adjusted risk ratio for natural death was 10.69 (p < .001) in the group with markedly elevated aspartate aminotransferase (> 80 U/L) and 4.71 (p < .01) in the mildly elevated group (40–80 U/L), with reference to the normal group (< 40 U/L). As for alanine aminotransferase, the adjusted risk ratios were 5.22 (p < .01) and 5.13 (p < .01). For the profiles at the latest admission during the study period, the use of antipsychotic drugs was identified to be associated with lowered risk. Part IV. After adjusting the covariates regarding the differences between two groups, only three indices of continuous indices had the adjusted z score greater than 0.5 (medium effect size), including PR duration (-0.9422), QTc duration (0.9062) and QTI (0.9021). The differences for these indices were around 1.0 standard deviation. Methamphetamine-dependent group had a higher proportion of arrhythmia than the healthy control group (17.6% vs. 8.7%, p=0.001), whereas other 4 indices were not significant different between two groups. Methamphetamine-dependent group were likely to have major abnormality of electrocardiogram compared with control group (4.4% vs. 1.3%, p=0.015), along with minor abnormality (47.8% vs. 39.7%, p=0.003). Additionally, stratified by the status of methamphetamine use, current users were not significantly different from recent users except higher heart beat rates. The electrocardiographic abnormalities were not associated with duration of methamphetamine use in methamphetamine group. Conclusions. Part I. A substantial proportion of the deceased died of natural deaths, but most of them died of unnatural deaths. The findings show significant evidence to provide a valuable insight for the premature deaths in the specific population. Part II. Both protective and risk factors for suicide mortality were found among inpatients with methamphetamine dependence, and the findings have implications for clinical intervention and prevention. Part III. This study highlights the damage of methamphetamine use to multiple organ systems, which is associated with natural death, along with the necessity of intensive follow-up among individuals with elevated aspartate or alanine aminotransferases. Part IV. This study confirmed the electrocardiographic abnormality in methamphetamine-dependent groups, predominantly shortened PR and prolonged QT intervals. Furthermore, it is highly suggestive for screening methamphetamine users with electrocardiographic abnormality, as a potentially treatable or manageable form of cardiotoxicity. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:43:06Z (GMT). No. of bitstreams: 1 ntu-100-D94842001-1.pdf: 1121425 bytes, checksum: e21b2f33a317d7ccac69eb4b3b0304e4 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 誌謝……………………………………………………………………1
中文摘要………………………………………………………………2 Abstract.. 6 Chapter 1: Introduction 18 1.1 Global endemic of methamphetamine 18 1.2 Methamphetamine induced physical harm, psychological harm, and premature death 18 1.3 Large cohort is needed for investigating the mortality outcome 18 1.4 Specific aims and hypothesis 19 Chapter 2: Causes of death of patients with methamphetamine dependence: a record-linkage study 20 2.1 Background 20 2.2 Material and Methods 20 2.2.1 Study population 20 2.2.2 Methamphetamine use in Taiwan 21 2.2.3 Data collection 21 2.2.4 Mortality case ascertainment 22 2.2.5 Statistical analyses 22 2.3 Results 23 2.3.1 Baseline information 23 2.3.2 Life spans 23 2.3.3 Standardized mortality ratios 24 2.4 Discussion 24 Chapter 3: Risk and protective factors for suicide: a nested case-control study 32 3.1 Background 32 3.2 Material and Methods 33 3.2.1 Study population 33 3.2.2 Case ascertainment and control selection 34 3.2.3 Data Collection 35 3.2.4 Statistical Analyses 36 3.3 Results 37 3.3.1 Demographics and Drug Use History 37 3.3.2 Psychiatric Symptomatology at the Latest Admission and After Discharge 37 3.3.3 Multivariate Analysis 39 3.4 Discussion 39 Chapter 4: Risk and protective factors for natural death: a nested case-control study 46 4.1 Background 46 4.2 Material and Methods 47 4.2.1 Setting and Patients 47 4.2.2 Data collection 48 4.2.3 Statistical Analyses 49 4.3 Results 49 4.3.1 Demographics and Drug Use History 49 4.3.2 Clinical Characteristics at the Index and Latest Admissions 50 4.3.3 Multivariate Analyses 51 4.4 Discussion 52 Chapter 5: Electrocardiographic abnormalities in patients with methamphetamine dependence 60 5.1 Background 60 5.1.1 Cardiovascular harm in methamphetamine users 60 5.1.2 Rare studies regarding electrocardiographic abnormalities in methamphetamine-dependent human subjects 61 5.1.3 The aims of this study (Part IV) 62 5.2 Material and Methods 63 5.2.1 Study subjects (Methamphetamine-dependent group) 63 5.2.2 Healthy control group 64 5.2.3 Standardized ECG readings based on Minnesota code classification 64 5.2.4 The status of methamphetamine use while performing the ECG exams 65 5.2.5 Collection of clinical data 65 5.2.6 Statistical analysis 66 5.2.7 Ethical Statement 67 5.3 Results 68 5.3.1 Difference of ECG indices between methamphetamine-dependent group and healthy controls (External control) 68 5.3.2 Gap.exe software (heat map) 68 5.3.3 Adjusted z score of ECG continuous indices (crude z score) 69 5.3.4 Figure (adjusted z score, based on the covariates derived from logistic regression) 69 5.3.5 Figure (adjusted z score, based on the covariates derived from Framingham study)(1998) 69 5.3.6 Odds ratio of detailed ECG categorical indices 70 5.3.7 The distribution of five major (categorical) ECG indices among the two groups (MAMP vs. healthy controls) 71 5.3.8 Characteristics of methamphetamine-dependent subjects stratified by gender 71 5.3.9 Comparison of continuous ECG indices among current users, recent (past) users, and healthy controls 72 5.3.10 Duration of methamphetamine use and ECG abnormality 72 5.3.11 Three extracted ECG indices (i.e. PR, QTc, QTI) in association with mental harm (psychotic symptoms) 72 5.3.12 Three extracted ECG indices (i.e. PR, QTc, QTI) in association with laboratory markers 73 5.3.13 All continuous indices of ECG stratified by the status of mortality 73 5.3.14 Three extracted ECG indices in association with all-cause, unnatural, and natural deaths (nested case control study) 73 5.4 Discussion 74 5.4.1 Strengths 74 5.4.2 Significant findings in this study 74 5.4.3 Current users vs. recent users 76 5.4.4 Duration of use vs. ECG abnormality 77 5.4.5 PR interval correlated with some of psychotic symptoms 77 5.4.6 Mortality and ECG indices 78 5.4.7 Limitations 78 Chapter 6: Conclusion and Perspectives 97 Supplemental materials 100 The Minnesota Code: The Description for Reporting ECG Variables 100 The Minnesota Code Classification System for Electrocardiographic Findings 104 Reference 110 Acknowledgements 115 The grants 115 The published papers 116 The papers under revision/preparation 116 The related published paper 116 | |
dc.language.iso | en | |
dc.title | 多面向探討一大型甲基安非他命依賴者世代族群的預後 | zh_TW |
dc.title | Outcome of A Large Cohort of Patients with Methamphetamine Dependence: A Multifacet Approach | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 簡國龍(Kuo-Liong Chien),李文宗(Wen-Chung Lee),陳喬琪(Chiao-Chicy Chen),王致皓(Chih-Hao Wang) | |
dc.subject.keyword | 甲基安非他命,預後,死亡,危險因子,自殺,自然死亡,心電圖, | zh_TW |
dc.subject.keyword | Methamphetamine,outcome,mortality,risk factor,suicide,natural death,electrocardiogram,abnormality, | en |
dc.relation.page | 120 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-29 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。